Of them, alpha-2-antiplasmin (SERPINF2) was positively associated with BMI and C-reactive protein, suggesting that SERPINF2 was a potential therapeutic target in metabolic diseases. This evidence concerns the gene SERPINF2 and Other metabolic disease.